Your session is about to expire
← Back to Search
Paxalisib for Central Nervous System Lymphoma
Study Summary
This trial is testing a drug to see if it can treat a type of cancer called primary central nervous system lymphoma.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My MRI shows my disease is not responding to treatment and can be measured.My high blood pressure is not controlled despite taking medication.I cannot swallow pills or have a stomach condition that affects medication absorption.I haven't had cancer treatment or investigational drugs in the last 4 weeks or 5 half-lives, and any side effects are mild.I have no active significant infections and no history of HIV or PML.I do not have severe health issues like serious lung problems, chronic diarrhea, or Crohn's disease.I have been tested for hepatitis B and C, and my results meet the study's requirements.I am at least 18 years old.I have an active disease that affects my whole body.I have no active cancer except for certain skin cancers or cancers I've been free from for 3+ years.I have mostly recovered from side effects of my previous treatments.I need treatment that affects how my body processes certain drugs.I have been treated with mTOR/PI3K inhibitors before.I am mostly able to care for myself.I take 8mg or less of dexamethasone or its equivalent daily, without increasing the dose for the last 2 weeks.My lymphoma in the brain has been confirmed by a biopsy.I have diabetes, but it's either type I, well-controlled type II on insulin, or uncontrolled type II.
- Group 1: PAXALISIB
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Can you speak to the safety of PAXALISIB for human consumption?
"We assign PAXALISIB a safety rating of 2 on our scale, as Phase II trials have yielded data that indicate its security but not yet the drug's efficacy."
How many participants is this clinical trial accommodating?
"Affirmative. Clinicaltrials.gov reveals that this clinical trial, launched on June 1st 2021, is accepting applications from volunteers. 25 participants will be accepted in total between the 2 sites involved in the study."
Does this experiment represent a pioneering effort within its field?
"As of now, 6 trials using PAXALISIB are still running in 51 urban centres and 7 countries. This molecule was initially tested by Kazia Therapeutics Limited back in 2018, with 27 participants participating in the Phase 1 trial. Since then, one study has been finished successfully."
Have any other experiments been conducted utilizing PAXALISIB as a treatment?
"Currently, 6 clinical trials are underway researching the effectiveness of PAXALISIB. One study is in its final phase while the rest are distributed across 77 sites with a majority located in Boston, Massachusetts."
Are there opportunities for volunteers to participate in this research?
"Confirmed; this clinical trial, first launched on the 1st of June 2021 is currently recruiting. Its details were most recently amended on 11th July 2022."
Share this study with friends
Copy Link
Messenger